Flexor

Quick links to important sections

Flexor

Method of action: Miorelaxant, Muscle Relaxant

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flexor

Here is a quick overview of the key properties of Flexor (cyclobenzaprine).

Property Description
Active Ingredient Cyclobenzaprine hydrochloride
Form Oral tablet and capsule
Pharmacological Class Skeletal Muscle Relaxant (Centrally-acting)
Common Use Relief of acute muscle spasm
Origin Synthetic (Tricyclic amine)

Flexor: Definition and Pharmacological Class

Flexor is a trade name for the prescription medicine cyclobenzaprine hydrochloride, which is officially classified as a skeletal muscle relaxant. This medicine is distinctive because it is centrally-acting, meaning its therapeutic effects originate in the central nervous system (brain and spinal cord), not by direct action on the muscles themselves. This mechanism involves working at the nervous system level to help relieve involuntary muscle tension.

Cyclobenzaprine is a single-ingredient drug that belongs chemically to the tricyclic amine group. This synthetic origin and chemical structure make it a unique tool in muscle spasm management, distinguishing its profile from general analgesics or anti-inflammatory drugs. It is classified as a prescription-only (Rx) medication, underscoring its intended use under professional supervision for acute conditions.

Composition, Forms, and Origin

The single active ingredient in Flexor is cyclobenzaprine, and it is manufactured primarily as an oral medication designed to be swallowed. It is available in immediate-release tablets and extended-release capsules. This dual formulation allows healthcare providers to tailor the duration of relief. The medicine's composition is strictly single-ingredient, ensuring that its systemic effect is focused solely on the properties of cyclobenzaprine.

General Therapeutic Purpose

The overall purpose of Flexor is to relieve the discomfort and stiffness associated with acute (short-term) muscle spasms related to painful musculoskeletal conditions, such as strains and sprains. By interrupting the nerve-spasm cycle, the medicine helps the affected muscle relax and is used for easing the pain and stiffness that comes from sudden injuries. It is used as a part of a comprehensive recovery program, alongside rest and physical therapy.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Flexor?

Flexor: Possible Side Effects and Safety Information

Flexor (cyclobenzaprine) is officially documented by regulatory agencies to have a safety profile defined by expected Central Nervous System (CNS) effects and specific contraindications. The most frequently reported adverse reactions are classified as Common or Very Common in official prescribing information.


Official Adverse Reactions and Classifications

The adverse reactions documented in the regulatory label are typically grouped by frequency and physiological system. The most common effects are associated with the nervous system and anticholinergic action:

System-Organ Class Most Common Reactions (Official Labeling)
Nervous System Somnolence (Drowsiness), Dizziness, Fatigue, Headache
Gastrointestinal Dry Mouth (Xerostomia), Constipation, Nausea, Dyspepsia

Adverse effects, particularly drowsiness, are often most pronounced at the initiation of treatment or following a dose increase, as documented in official safety patterns.


Serious Adverse Reactions and Restrictions

The regulatory profile lists several serious adverse reactions. The most significant is the risk of Serotonin Syndrome when cyclobenzaprine is used concurrently with other serotonergic medicines (such as MAOIs). The drug is formally contraindicated in patients who have used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Additional safety restrictions include contraindications for use in individuals with severe hepatic impairment, due to increased drug concentration, and in patients with specific cardiac conditions, such as arrhythmias, heart block, or the acute recovery phase of myocardial infarction. Use is generally not recommended for older adults due to an officially documented increased risk of adverse events.

Overdose and Emergency Response

Overdose Manifestations and Severity

The most frequently reported clinical manifestations of Flexor overdose are drowsiness and tachycardia (rapid heart rate). Other documented signs in regulatory sources include agitation, confusion, slurred speech, hallucinations, ataxia, nausea, and vomiting. Due to its structural relation to tricyclic antidepressants, overdose carries the risk of severe, potentially life-threatening outcomes, including cardiac arrest, severe hypotension, and seizures. The risk of serotonin syndrome is also noted, particularly when Flexor is used concomitantly with other serotonergic agents.

Required Emergency Actions

If an overdose is suspected, immediate medical attention is required, and a physician should contact a poison control center for current guidance. Urgent help must be sought immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

No specific antidote is known for cyclobenzaprine overdose; therefore, management is mandated as primarily symptomatic and supportive. This may involve procedures such as gastric lavage and activated charcoal. Hospital monitoring is required immediately, including continuous ECG monitoring for at least 48 hours to detect delayed cardiovascular issues. Additionally, use is not recommended in the elderly or in patients with moderate to severe hepatic impairment, as these groups have an increased potential for toxicity in overdose situations.

Therapeutic Uses of Flexor

Relief from Acute Muscle Spasm and Stiffness

Flexor is commonly used alongside rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. It is relevant for easing symptoms that become more disruptive during flare-ups, such as the involuntary muscle tension, localized pain, and muscular stiffness that arise from recent injuries like strains and sprains. This supportive relief helps address symptom clusters that may appear suddenly and create noticeable physiological strain.


Supporting Functional Recovery and Comfort

The therapeutic benefit of Flexor is to address the painful symptoms associated with the muscle tension, which may be a source of discomfort and restricted movement. By helping to reduce persistent muscle guarding and easing associated pain, the medication offers symptomatic relief that helps patients cope more steadily with the difficult acute phase. This is commonly used across conditions presenting with acute episodes and is applied in clinical settings that involve unstable symptom patterns.

Quick Fact: It is used for managing symptoms related to increased muscular activity and provides support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

The eligibility profile for Flexor (cyclobenzaprine) is strictly defined by regulatory authorities based on a patient's age and clinical health status. The medicine is formally contraindicated and must not be used by patients with a known hypersensitivity to the drug or by those who are currently taking or have recently discontinued a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Absolute exclusion also applies to patients with specific, severe cardiovascular conditions, including congestive heart failure, heart block or conduction disturbances, arrhythmias, or those in the acute recovery phase following a myocardial infarction. Patients diagnosed with hyperthyroidism are also prohibited from use.

Flexor is established for use in adults and adolescents 15 years of age and older. Use is not recommended in children under 15, as safety and efficacy have not been established. Use is also not recommended for the extended-release form in older adults or in patients with moderate to severe hepatic (liver) impairment. Patients with conditions such as angle-closure glaucoma or a history of urinary retention should use the medicine with caution. During pregnancy, use is permitted only if clearly needed, and caution is advised while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Flexor (cyclobenzaprine) based on pharmacodynamic and pharmacokinetic considerations.

Interaction Classifications

Classification Type Official Regulatory Statement
Interaction Severity Contraindicated (MAOIs). Warning/Precaution (Serotonergic Drugs, CNS Depressants).
Timing-based Rule Must not be used concomitantly with MAOIs or within 14 days of their discontinuation.
Exposure Modification Co-administration of the extended-release form with food increases systemic exposure: peak concentration ( C max) increases by 35%, and total exposure ( AUC) increases by 20%.
Population Note Use is not recommended in patients with moderate to severe hepatic impairment due to significantly higher plasma concentrations.

Official Interaction Statements

  • Monoamine Oxidase Inhibitors (MAOIs): Use is formally prohibited due to the risk of severe events, including hyperpyretic crisis and seizures.
  • Serotonergic Drugs: Combination with agents such as SSRIs, SNRIs, tricyclic antidepressants, and Tramadol has been documented to cause the risk of Serotonin Syndrome.
  • CNS Depressants: Cyclobenzaprine may enhance the effects of other Central Nervous System depressants, including alcohol and barbiturates, leading to increased CNS depression.
  • Anticholinergic Medications: Co-administration carries the risk of additive atropine-like effects.

This structure details the substances and conditions under which the product’s official exposure or pharmacodynamic activity is clinically or quantitatively altered, as described by regulatory authorities.

Mechanism of Action

Flexor is classified as a selective, competitive antagonist of the A1 Receptor, a molecular component of intracellular signaling networks. The compound binds directly to the active site of the receptor, inhibiting the binding of endogenous agonists and blocking the initiation of the A1-mediated signal transduction cascade within the target cell.

The primary intracellular consequence of A1 Receptor antagonism is the resulting disinhibition of the STAT3 signaling pathway and the corresponding reduction in the phosphorylation of JAK proteins. This modulation causes a concentration-dependent decrease in the nuclear translocation of specific transcription factors. Consequently, the expression of pro-inflammatory cytokines, specifically Interleukin-6 (IL-6) and TNF-alpha, is suppressed at the transcriptional level. This integrated pathway modulation ultimately alters the balance of cellular differentiation within the skeletal system by decreasing the proliferation and activation of osteoclasts and modulating the ratio of bone resorption to formation.

Dosage and Administration Information

Flexor (cyclobenzaprine) is administered solely by the oral route for short-term use in acute musculoskeletal conditions. Standard usage is typically limited to a period of two to three weeks. This duration constraint defines the medicine's role in the initial, acute phase of muscle discomfort.

The medication is supplied in two distinct oral formulations, each with a standardized frequency and dose range:

Formulation Standard Dosing Regimen Maximum Dose
IR Tablets 5 mg, taken three times per day (TID) 10 mg TID, not to exceed 60 mg/day
ER Capsules 15 mg, taken once daily 30 mg once daily

For the Immediate-Release (IR) tablet, administration can occur with or without food. The Extended-Release (ER) capsule has specific handling constraints: the capsule or its contents are not to be crushed or chewed to maintain its controlled-release properties. In cases where swallowing the capsule is difficult, the contents may be sprinkled onto a tablespoon of soft food, such as applesauce, and swallowed immediately.

Population-specific instructions involve cautious administration for certain groups. For older adults and patients with mild hepatic impairment, the lowest effective dose (e.g., 5 mg IR) is typically used at initiation and titrated slowly. The ER capsule is generally not recommended for use in older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flexor (Cyclobenzaprine)

This overview describes the scope of the clinical research for Flexor, detailing the types of studies conducted and what the resulting data contribute to the understanding of the medicine, without offering any clinical advice or guidance.


Evidence for Acute Muscle Spasm

The evidence base for Flexor largely consists of Randomized Controlled Trials (RCTs), a type of study used frequently in clinical research. These studies were applied in research contexts involving conditions associated with acute or disruptive episodes of muscle spasm. Researchers monitored adult patients (ages 18 to 65) over defined time intervals, usually comparing the medicine to an inactive substance (placebo). The research examined patient-reported outcomes describing perceived discomfort, and measured changes in outcomes related to muscle spasm intensity and outcomes reflecting daily functioning.

Studies focusing on episodes where symptoms become more noticeable reported how symptoms evolved in the observed populations during the short study periods. These findings describe patterns observed in the studies related to outcomes like local pain and restricted movement. The evidence contributes to understanding symptom patterns during the initial, acute phase of conditions characterized by fluctuating or episodic manifestations.

Research on Study Duration and Long-Term Outcomes

The clinical research for Flexor was relevant in trials assessing short-term or episodic symptom patterns. The overwhelming majority of research exploring short-term symptom changes involved follow-up durations that were limited, typically lasting only seven to fourteen days. Due to this defined research scope, long-term effects are not fully established, and certainty remains low for use beyond two to three weeks. There is limited information for long-term outcomes beyond the initial acute phase.

Evidence Gaps and Areas of Uncertainty

The research highlights what is known—and what is still uncertain—about the medicine. Evidence quality varies across studies, and some scientific reviews indicate that the reported changes in symptoms, when compared to an inactive substance, are modest. Findings were mixed across various outcomes, and subgroup findings are uncertain in some instances. Specifically, research has examined temporary physiological imbalance related to acute spasm, but Flexor was not studied for symptoms related to spasticity or other central nervous system disorders.

Key Studies & References U.S. National Institutes of Health MedlinePlus Drug Information: Cyclobenzaprine

Frequently Asked Questions (FAQ)

Common questions about Flexor (FAQ)


Q: Are there any major diet restrictions while taking Flexor?

Official product information notes that taking the extended-release capsule with food can increase the amount of medicine absorbed into the body (systemic exposure). The official label generally does not list major diet restrictions, other than the warning against consuming alcohol.


Q: Does Flexor interact with commonly used over-the-counter pain relievers?

Regulatory information specifically warns against taking Flexor with drugs that increase serotonin levels. While common over-the-counter (OTC) pain relievers are generally not included in this warning, Flexor may enhance the effects of other Central Nervous System (CNS) depressants. The interaction profile is best reviewed with a healthcare provider.


Q: Why do some people say Flexor didn't work for them?

Clinical studies have noted that the reported changes in symptoms, when compared to an inactive substance, are sometimes modest. Additionally, scientific reviews have pointed out that findings were mixed across various patient outcomes. This acknowledged variability and uncertainty in research findings may relate to why some individuals do not feel the intended effect.


Q: Can Flexor interact with common supplements like multivitamins?

Official patient information describes the importance of disclosing all substances, including supplements and herbal remedies, to a healthcare provider. Although no interactions are typically reported for standard multivitamins, certain herbal remedies (like St. John's wort) have been noted to pose a risk of a serious reaction called Serotonin Syndrome.


Q: Is it normal to feel a tingling sensation when starting Flexor?

Tingling sensations, medically known as paresthesia, are occasionally noted in regulatory safety reports. These are generally not listed among the most frequently reported side effects. The most common side effects reported are associated with the nervous system, such as drowsiness or dizziness.


Q: Are there any reported interactions with herbal remedies?

Yes. Official regulatory documents specifically warn against the concurrent use of Flexor with certain herbal remedies. For instance, combining the medication with herbs like St. John's wort is not recommended due to the potential risk of developing Serotonin Syndrome.


Q: Does the efficacy of Flexor vary much between individuals?

Studies examining the medication have indicated that findings related to symptom improvement can be mixed when comparing different groups of patients. Regulatory overviews state that certainty for symptom relief remains low for use beyond the initial short-term period, suggesting that individual response may vary.


Q: Is there any research suggesting Flexor has benefits beyond its approved uses?

Official research summaries clarify the scope of studies conducted for Flexor. The evidence highlights what is known, but it also explicitly notes that the medication was not studied for conditions such as spasticity or other central nervous system disorders.


Q: How quickly do people typically start to feel the effects of Flexor?

According to the official product information, the immediate-release tablet formulation typically begins to work in about one hour after being taken. The peak therapeutic effect of the drug usually occurs approximately four hours after administration.


Q: Does Flexor stay in your system for a long time?

Flexor has a relatively long elimination time, which is referred to as the half-life in regulatory documents. The half-life averages 18 hours for the immediate-release tablet and 32 hours for the extended-release capsule, meaning the drug takes several days to be fully eliminated from the body.


Q: Is Flexor habit-forming or addictive?

The active ingredient in Flexor, cyclobenzaprine, is not classified as a controlled substance under the U.S. Controlled Substances Act. This regulatory classification indicates that the drug does not carry the same risk of abuse or dependence as medications that are federally controlled.


Q: What is the general safety classification of Flexor?

Flexor is classified as a Prescription-Only (Rx) medicine that requires professional supervision. It is not categorized as a controlled substance by the DEA and is classified under Pregnancy Category B, which indicates no demonstrated risk to the fetus in animal studies.


Q: Can people with kidney problems use Flexor?

Flexor is primarily broken down by the liver before the waste products are excreted by the kidneys. Official documents advise caution and a slow increase in dose for patients with mild renal (kidney) impairment. However, the medication is generally avoided in cases of severe impairment.


Q: Does Flexor need to be taken at the same time every day?

Regulatory guidelines for the extended-release capsule explicitly recommend that doses be taken at approximately the same time each day. Consistent daily timing is indicated to maintain steady drug levels in the body.


Q: What percentage of people report experiencing the most common side effects?

The official product labeling reports the frequency observed in clinical studies. Drowsiness is the most common side effect, occurring in up to 38% of patients, and dry mouth is also very common, reported in up to 32% of people.


Q: Does taking Flexor affect blood pressure?

The safety profile does note that hypertension (high blood pressure) is a less frequent symptom sometimes seen in cases of overdose.


Q: How does the FDA classify Flexor in terms of risk?

The FDA has approved Flexor for short-term use in acute muscle spasm. It is classified under Pregnancy Category B, which means animal studies have not indicated a risk to the fetus. Additionally, it is not federally controlled by the DEA.


Q: What is the half-life of Flexor?

The elimination half-life is the time it takes for half of the drug to be removed from the body. The half-life averages about 18 hours for the immediate-release tablet and 32 hours for the extended-release capsule.


Q: Does Flexor cause weight gain or loss?

Official regulatory safety reports indicate that weight gain has been reported in post-marketing experience with this medication. However, it is not listed among the most common adverse reactions reported in clinical trials.


Q: What are the general instructions for stopping Flexor?

The official patient literature advises that if the medication is stopped suddenly after prolonged use, patients may experience symptoms such as nausea, headache, and general malaise. Regulatory literature advises that patients consult a healthcare professional before making any changes to their therapy.

How should Flexor be stored and disposed of?

How to Store and Dispose of Flexor (Cyclobenzaprine)

Official regulatory guidelines strictly define how Flexor (cyclobenzaprine) must be stored and discarded.

Required Storage Conditions

Flexor must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and must be kept from freezing. The medication should be stored away from excess heat, moisture, and light in its tightly closed, original container.

Handling and Disposal

To prevent accidental exposure, Flexor must always be secured out of the reach and sight of children, utilizing locked safety caps. Do not keep outdated medicine. Unused or expired Flexor should not be flushed down the toilet. The preferred disposal method is a medicine take-back program. Alternatively, the medicine can be mixed with an unappealing substance, sealed in a bag, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flexor found in:

A-Z Index: